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Abstract: Determining the properties of nanoparticles obtained by novel methods and defining the
scope of their application as drug carriers has important practical significance. This article presents
the pioneering studies concerning high degree incorporation of cytarabine (AraC) and methotrexate
(MTX) into liposome vesicles. The main focus of this study were cytarabine-methotrexate-
dipalmitoylphosphatidylcholine (DPPC) interactions observed in the gel and fluid phases of DPPC
bilayers. The proposed new method of use the Transmittance2919/2850 ratio presented in our research
is sensitive to subtle changes in conformational order resulting from rotations, kinks and bends of the
lipid chains. The transition temperatures characterized by Fourier Transform Infrared Spectroscopy
(FT-IR) were consistent with the results obtained by Differential Scanning Calorimetry (DSC).
Transmission Electron Microscopy (TEM) was used in order to determine the size and shape of
the liposomes obtained. The mutual interactions occurring between the drugs studied and the
phospholipids were analyzed using the Nuclear Magnetic Resonance (NMR).
Keywords: delivery systems; cytarabine; methotrexate
1. Introduction
Important issues concerning transport of therapeutic substances, drug carriers and therapeutic
delivery systems (TDS) include form of the drug, its formulation, structure and/or technology applied.
The paramount objective is to modify and improve bio-availability of the therapeutic effect of the
medicinal agent, and/or to minimize side effects by influencing its pharmacokinetic-pharmacological
parameters. The premises of modern pharmaceutical technology are associated with a desire to achieve
optimum therapeutic drug concentration at its site of action, usually by modifying the process of drug
release. It has been estimated that approximately 40%–50% of new therapeutic substances would
require the use of TDS [1].
The developments in material chemistry research, especially nanotechnology, have led to the
acquisition of new biocompatible materials that can be used in formulating novel drug carriers.
The results of these discoveries have translated into a number of medicinal TDS which have been
registered by the FDA (US Food and Drug Administration) over the past few decades. Most TDS are
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polymer-drug conjugates, where the polymer unit is made up of polyethylene glycol or copolymers of
lactic acid and glycolic acid. Nonetheless, many drugs can also be transported by lipid-based structures,
i.e., micelles and liposomes. Liposomes are spherical structures formed by a single lipid bilayer or
multiple, concentric bilayers which enclose part of the aqueous medium in which they are suspended.
This bilaminar structure is made up of amphiphilic phospholipids arranged in two adjacent layers.
The hydrophilic portions of the lipids, forming the double shell of the liposome, are positioned towards
the water phase, while the nonpolar lipophilic fatty acid chains of both lipid layers are directed towards
each other to form an inner hydrophobic layer.
A notable feature of liposomes is their biocompatibility. Liposomal membrane composition similar
to natural components of the cell membrane causes the liposomes to be non-toxic and biodegradable.
Another important feature is their size. Depending on the method of liposome preparation, they
may vary in size from dozens of nanometers to several micrometers, with a membrane thickness of
approximately 4 nm. The size of liposomes is crucial for rate of their removal from the bloodstream
by macrophages of the MPS (Mononuclear Phagocyte System). Shortly after injection into the blood
circulatory system, liposomes start interacting with plasma proteins (opsonins), which, when adsorbed
on the surface of liposomes, lead to their removal by the MPS. Liposomes with a diameter >100 nm
are caught by the MPS much quicker and easier. On the other hand, small vesicles (<100 nm) have a
longer circulation time in the bloodstream [2]. The use of small liposomes with a diameter of about
100 nm allows them to penetrate through the walls of blood vessels. This is particularly important at
sites of inflammation, wherein the vessel walls exhibit considerable spaces between cells. The gaps
are from 100 to 200 times larger than those occurring in healthy blood vessels [3,4]. Through these
gaps, liposomes can easily penetrate and concentrate themselves at the site of inflammation. In the
case of healthy tissues, vascular walls are poorly permeable, and the spaces between the cells range
between approximately 20 to 40 nm. As a result, liposomes “do not exit” the bloodstream and remain
there until they reach their destination or are removed. Liposomes remaining in the bloodstream
for an extended period of time are biodegraded gradually, thereby providing a stable level of drug
activity. This “passive targeting” is extensively used by nanotechnology-based delivery systems,
including liposomes for drug delivery and treatment of tumors, bacterial or viral infections and many
other diseases.
This article presents the pioneering studies concerning high degree incorporation of cytarabine
(AraC) and methotrexate (MTX) (Figure 1) simultaneously into liposome vesicles obtained by a
modified reverse-phase evaporation method (mREV).
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Figure 1. Chemical structures of (A) methotrexate; (B) cytarabine. 
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leucovorin, cytarabine (COMLA), doxorubicin, methotrexate, vincristine, prednisone, leucovorin, 
cytarabine, cyclophosphamide, etoposide (AMOPLACE), carmustine, vincristine, cytarabine, methotrexate 
(BVAM), fluorouracil, methotrexate, cytarabine, cyclophosphamide, doxorubicin, vincristine, 
Figure 1. Chemical structures of (A) methotrexate; (B) cytarabine.
Based o clinical studi s, there is a lot f information that contain therapeutic protocols
concerning the use of cytarabine and methot exate tog t er (cyclophosphamide, vi cristine, methotrexate,
leucovorin, cytarabine (COMLA), doxorubicin, methotrexate, vincristine, prednisone, leucovorin,
cytarabine, cyclophosphamide, etoposide (AMOPLACE), carmustine, vincristine, cytarabine,
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methotrexate (BVAM), fluorouracil, methotrexate, cytarabine, cyclophosphamide, doxorubicin,
vincristine, prednisone (F-MACHOP), cyclophosphamide, high-dose methotrexate, high-dose
cytarabine (HIC-COM), methotrexate, vincristine, prednisone, cytarabine, cyclophosphamide,
etoposide (MOPLACE)). Until recently, commonly used monotherapy was increasingly being replaced
by a combination and targeted therapy. Targeted therapy by the use of compounds that inhibit specific
target molecules can provide new perspectives on the treatment of cancer. The use of multidrug
therapy, in contrast to conventional chemotherapy, has many advantages. Cancer cells are attacked by
multiple drugs that disrupt different stages of the cell reproduction cycle. For instance, minimization
of side effects is another goal of combination therapy. The use of liposomes in the transport of
drugs can minimize the occurrence of multidrug therapy side effects. It is noteworthy that the
presented study was mainly focused on cytarabine-methotrexate-dipalmitoylphosphatidylcholine
interactions in the 20–47 ◦C temperature range, i.e., in the gel (Pβ’) and fluid (Lα) phases of
dipalmitoylphosphatidylcholine (DPPC) bilayers.
The knowledge of drug carriers’ thermotropic properties provides a lot of practical information at
the primary studies stage. The extent and rate of drug release arising from thermotropic properties
determine the practical application of newly obtained structures. The proposed new method of
using the Transmittance2919/2850 ratio presented in our research is sensitive to subtle changes in
conformational order resulting from rotations, kinks and bends of the lipid chains. The transition
temperatures characterized by Fourier Transform Infrared Spectroscopy (FT-IR) were consistent with
the results obtained by Differential Scanning Calorimetry (DSC). Transmission Electron Microscopy
(TEM) was employed in order to determine the size and shape of the liposomes obtained. Mutual
interactions occurring between both studied drugs and the phospholipids were analyzed using NMR.
The results presented herein are a continuation of research on the encapsulation of two drugs into
liposomes, one of which has been cytarabine [5–8]. Cytarabine is a chemotherapeutic used to treat
leukemia and lymphoma. The other drug studied herein, methotrexate, has been employed to treat
breast, head and neck, lung and bladder neoplasms. However, the associated toxicity and side effects
of both warrant evaluation of novel efficient delivery systems to improve the therapeutic efficiency of
such drugs [9].
2. Results and Discussion
2.1. Liposome Properties
Several imaging techniques (SEM—Scanning Electron Microscopy, TEM, AFM—Atomic Force
Microscopy, Confocal Microscopy) can be used to determine the size and shape of liposomes.
Ruozi et al. suggested freeze–fracture to be the optimal method for studying biological samples
in this context [10]. In the present study, we used a simpler and faster imaging procedure based on
TEM. In this method, liposomes are embedded in a suitable electron-dense material providing high
contrast and good reproducibility. Uranyl acetate (2%), which was used herein, penetrates only slightly
into the interior of liposomes, and mostly binds to the phosphate groups of the external lipid layer.
Thus, it allows for an assessment of the shape and size of the resulting liposomes (Figure 2). Based on
these results, it was found that the LDPPC/AraC/MTX liposomes obtained via the mREV method are
characterized by a regular spherical shape and a size of ≤120 nm.
The drugs used in the preparation of the liposomes were used at 1:1 molar ratio. The determination
of the encapsulated cytarabine and methotrexate was carried out according to the method described
by Kaiser et al. [11]. The encapsulation efficiency was determined as the mass ratio between the
amount of the drug incorporated in liposomes and the ratio used in the liposome preparation.
The encapsulation efficiencies of AraC and MTX in LDPPC/AraC/MTX were found to be 86.3% (AraC)
and 86% (MTX). In order to determine the stability of the liposomal preparations, the percentage of
cytarabine and methotrexate release from the liposomes was monitored for several weeks. The drug
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release measurements were performed according to the method reported by Jin et al. [12]. The results
of the stability study, based on weekly determinations of the release rate, are shown in Figure 3.Molecules 2016, 21, 1689 4 of 11 
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Figure 3. In vitro cytarabine (AraC) and methotrexate (MTX) release from the LDPPC/AraC/MTX liposomes 
stored at +4 °C for a period of four weeks. 
The results obtained for a four-week-long incubation of liposomes at +4 °C have demonstrated 
that the simultaneous incorporation of cytarabine and methotrexate into liposomes (molar ratio 1:1) 
takes place on a competitive basis, and as the result of this process, double release of cytarabine 
from liposomes occurs compared to methotrexate. 
2.2. Thermodynamic Properties of Phase Transition 
Knowledge of the size and shape of liposomal structures, made possible by the applied TEM 
method, has been extremely important at the current stage of research on the proposed liposomal drug 
formulation. Other important aspects of this basic research involve recognition of thermodynamic 
changes in phospholipid membranes and interactions between the incorporated drugs and 
phospholipid molecules. The Differential Scanning Calorimetry (DSC) and FT-IR methods enabled 
a determination of chain fluidity and mobility alterations, and ultimately permitted correlation of 
the results with the spectroscopic structural modifications on a molecular level. Figure 4 represents 
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(LDPPC/AraC/MTX) obtained by the modified reverse-phase evaporation method (mREV), negatively
stained (2% uranyl acetate solution) on a carbon-coated copper grid, magnification: 50,000 times;
at room temperature.
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Figure 3. In vitro cytarabine (AraC) and methotrexate (MTX) release from the LDPPC/AraC/MTX
liposomes stored at +4 ◦C for a period of four weeks.
The results obtained for a four-week-long incubation of liposomes at +4 ◦C have demonstrated
that the simultaneous incorporation of cyt rabine and methot exate into liposom s (molar ratio 1:1)
takes place on a competitive basis, and as the result of this process, double release of cytarabine from
liposomes occurs compared to met otrex te.
2.2. Thermodynamic Properties of Phase Transition
Knowledge of the size and shape of liposomal structures, made possibl by the applied
TEM method, has been extre ely important at the current stage of research on the proposed
liposomal drug formulation. Other important aspects of this basic research involve recognition
of thermodynamic changes in phospholipid membranes and interactions between the incorporated
drugs and phospholipid molecules. The Differential Scanning Calorimetry (DSC) and FT-IR methods
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enabled a determination of chain fluidity and mobility alterations, and ultimately permitted correlation
of the results with the spectroscopic structural modifications on a molecular level. Figure 4 represents
changes in the Transmittance2919/2850 ratio of LDPPC and LDPPC/AraC/MTX liposomes and calorimetric
scans from LDPPC and LDPPC/AraC/MTX liposomes.
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(A2,B2) plots of (A) control DPPC liposomes and (B) DPPC liposomes containing cytarabine and 
methotrexate. Lβ’—tilted gel phase; Pβ’—ripple gel phase; Lα—liquid crystalline phase; Cp—heat 
capacity at constant pressure. 
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obtained by DSC is 41.30 °C ± 0.08, and that obtained by FT-IR is 41.28 °C ± 0.06. After incorporation of 
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Figure 4. Transmittance2919/2850 ratio (A1,B1) vs. temperature and Differential Scanning Calorimetry
(A2,B2) plots of (A) control DPPC liposomes and (B) DPPC liposomes containing cytarabine and
methotrexate. Lβ’—tilted gel phase; Pβ’—ripple gel phase; Lα—liquid crystalline phase; Cp—heat
capacity at constant pressure.
The dynamics and structural changes occurring in the phospholipid membrane resulted in
observing tw transition phases. The first one, known as t pre-transition phase (Tp 35 ◦ ) is the
transi io from Lβ’ phase to Pβ’ phase. The second, called the main transition phase (Tc ~41 ◦C), is the
tr nsition from Pβ’ phase t Lα phase. Below the pre-transition temperature (Tp), the lipid chains are
in all-trans conformation [13]. T istra -Nagle t al. co c uded tha , in Lβ’ phase, the lipid ch ins are
tilted with respect to the normal membrane at a angl of about 32◦ [14]. Above the temperature of
the pre-transition phase, the acyl chains remain in the folded gel phase.
FT-IR spectra of blank (LDPPC) liposomes and of liposomes containing cytarabine and methotrexate
(LDPPC/AraC/MTX) were obtained at 20–47 ◦C and were recorded in the 3000–800 cm−1 range.
When analyzing the FT-IR spectra of the lipid samples, it is easy to see that the methylene stretching
bands in the 3000 cm−1–2850 cm−1 region are the most intense ones in the whole spectrum.
The symmetric stretching modes in the methylene groups (CH2) allow for an investigation of the main
phase transition temperature (Tc). The values for the main phase transition temperature Tc obtained by
FT-IR and DSC methods are comparable (Table 1). For the referenced liposomes, the temperature Tc
obtained by DSC is 41.30 ◦C ± 0.08, and that obtained by FT-IR is 41.28 ◦C ± 0.06. After incorporation
of the drugs, this temperature increases slightly as a result of changes in the packing of molecules
in the film as well as changes in the conformation of lipids. The incorporation of drugs also has a
significant impact on the temperature of the pre-transition phase (Tp). The results of the Maghraby
et al. study concerning the interaction of drugs having differing degrees of solubility in water with
phospholipid membranes suggest that the pre-transition phase is the result of, first, the rotation
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of the polar part of the phospholipid, and, second, conformational changes of the phospholipid
membrane [15]. Thus, any alteration of the membrane composition with additional ingredients will
ultimately affect the temperature of the pre-transition phase. The incorporation of cytarabine and
methotrexate into phospholipid membranes resulted in the increase of Tp temperature by nearly 2 ◦C.
This indicates that the analyzed drugs penetrate only partially into the bilayer (into the lipophilic
region) and always remain in direct contact with the polar portion of dipalmitoylphosphatidylcholine.
Table 1. Pre-transition temperature (Tp) and main transition temperature (TC) determined for LDPPC
and LDPPC/AraC/MTX liposomes by DSC and FT-IR method.
Liposomes Phase Transition Temperature (◦C)
DSC FT-IR
Tp TC Tp TC
LDPPC 34.64 ± 0.14 * 41.30 ± 0.08 * nd 41.28 ± 0.06 *
LDPPC/AraC/MTX 36.39 ± 0.12 * 41.81 ± 0.09 * 36.02 ± 0.11 * 41.95 ± 0.08 *
nd—not detected; * Standard error.
The FT-IR method also allows estimating the degree of membrane ordering. The use of the
intensity ratio of two bands as an order parameter (I2850/I2880) was first proposed by Levin and Lewis
in 1990 [16]. Since then as reported by Potamitis and co-workers [17], these bands have been commonly
used to monitor changes in the lateral packing properties and mobility of the lipid chain in both gel
and liquid crystalline bilayer systems. The Transmittance2919/2850 ratio presented in our research,
similarly to the intensity ratio I2850/I2880 proposed by Levin and Lewis, is sensitive to subtle changes in
conformational order resulting from rotations, kinks and bends of the lipid chains. The isobaric curve
derived from changes in the position of symmetrical and asymmetrical stretching vibration bands
shows three temperature ranges for reference liposomes as well as for liposomes with incorporated
cytarabine and methotrexate (Figure 4A1,B1). The phase transitions determined by this method
are consistent with the data received using the DSC method. It is also clear that cytarabine and
methotrexate increase the degree of the membrane ordering. The degree of membrane ordering is
10-fold less for the reference liposomes as compared to the LDPPC/AraC/MTX (∆Transmittance2919/2850
increases from 0.04 to 0.37).
Observation on the basis of ∆Transmittance2919/2850 growth in the degree of membrane order
after incorporation of cytarabine and methotrexate is comparable to the increase in the value of the
parameter S, which has been determined by EPR spectroscopy used for cholesterol incorporated into
liposomes [18,19]. As can be seen from Figure 4A1,B1, cytarabine and methotrexate induce the greatest
changes in the conformation of lipids already in the tilted gel phase.
2.3. DPPC Liposomes Containing Cytarabine and Methotrexate: Studies by FT-IR and NMR Spectroscopy
As presented in Figure 5, changes in the FT-IR spectrum are visible in the entire spectral region.
The changes observed for each band, resulting from the incorporation of the analyzed drugs, are shown
in Table 2. The principal band between 3000 cm−1 and 2800 cm−1 represents the C–H stretching modes
with the maxima at 2919 cm−1 and at 2850 cm−1 corresponding to antisymmetric and symmetric
stretching in the CH2 groups of alkyl chains, respectively. No contribution from the antisymmetric
stretching vibration in the CH3 groups at 2956 cm−1 was observed. In the spectral region between
1800 cm−1 and 1500 cm−1, the stretching vibrations of the C–O groups were observed. This band is
attributed to the stretching vibration of the C–O group in the ester band. As presented in Table 2,
spectral changes in this region arise both from the incorporation of cytarabine as well as methotrexate.
The biggest inductive influence of oxygen in the ester fragment of the DPPC molecule causes the
increase of frequency of the C–O group (1734.5→1738 cm−1) in liposomes containing methotrexate.
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Table 2. Assigned bands of the FT-IR spectra of LDPPC, LDPPC/AraC, LDPPC/MTX, LDPPC/AraC/MTX liposomes.
Assignment *
Wavenumber (cm−1)
LDPPC LDPPC/AraC LDPPC/MTX LDPPC/AraC/MTX
νas (CH3) 2955.5 2956.0 2956.0 2956.0
νas (CH2) 2919.0 2918.5 2918.5 2919.0
νs (CH2) 2850.0 2850.5 2850.5 2850.5
νas (C=O) for ester 1734.5 1732.0 1738.0 1738.0
νas (PO2−) 1214.5 1215.0 1222.0 1219.5
νs (PO2−) 1085.0 1087.0 1088.5 1089.0
νas (N+-CH3) 970.0 970.0 971.5 972.0
γr (CH2) nd nd 721.5 721.5
* νs—symmetric stretching vibration; νas—antisymmetric stretching vibration; γr—rocking vibration;
nd—not detected.
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The effects include changes in electron density and bond lengths. A strong wide band in the 
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Figure 5. FT-IR spectra of control LDPPC liposomes and li oso es containing cytarabine and methotrexate.
The effects include changes in electron density and bond lengths. A strong wide band in the
spectral region of ~1214 cm−1 was also observed. This band is attributed to the asymmetrical stretching
vibrations of the –PO2− group in DPPC. The changes in the area of the phosphate group were weak
for LDPPC/AraC liposomes. Much more significant (1214.5→1222 cm−1) changes in the analyzed area
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of the spectrum were caused by the incorporation of methotrexate into phospholipid membranes.
The vibrations of polar head groups are represented by symmetric PO2− stretching (~1085 cm−1)
and antisymmetric N+–CH3 stretching (~970 cm−1) vibrations. The simultaneous incorporation of
cytarabine and methotrexate into liposomes increases the frequency of vibration of the PO2− by
4 cm−1. The observed changes in the polar head groups area, resulting from the incorporation of drugs,
also confirm the changes in temperature of the pre-transition phase (Table 1). It is also known that the
molecular reorientation of polar head groups from the horizontal to the vertical position is strongly
endothermic [20].
As expected, NMR spectroscopy has confirmed the presence of interactions between the analyzed
drugs and the phospholipids forming the liposomal membrane (Figure 6). Schematically, the liposomal
membrane can be divided into three areas: the polar area, the hydrogen belt and the hydrophobic
core. Partial positioning of cytarabine and methotrexate in the polar area of the membrane has
been confirmed by correlation signals between H4 cytarabine protons and protons of the quaternary
ammonium group (1), and between the protons of the quaternary ammonium group and the H21
methotrexate protons (2). Moreover, a cross peak between H4 (Figure 1) cytarabine protons and
dipalmitoylphosphatidylcholine protons was observed (3). In order to facilitate the interpretation of
the 2D NOESY spectra, the structure and 1H-NMR spectrum of dipalmitoylphosphatidylcholine has
been added in Supplementary Figure S1.
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Figure 6. 2D NOESY spectra of LDPPC/AraC/MTX liposomes obtained at 25 ◦C (left panel) and at 47 ◦C
(right panel).
With referen e to our previous research on the posit oning of ytarabine in the liposome
membrane [7,8], it may b concluded that the sugar residue of cytarabin , which contains hyd xyl
groups, orients itself towards the lipid–water interface, and the pyrimidine ri g penetrates int the
glycerol backbone area. Raising the analytical temperature to 47 ◦C (Figure 6, right panel) confirmed
the location of methotrexate in the hydrophobic area of the membrane. In the 2D NOESY spectrum at
47 ◦C, NOEs are seen between the H26 and H27 protons of methotrexate (Figure 1) and the (CH2)n
protons of the alkyl chain of the lipid bilayer (4) and the terminal methylene group (5). Given the results
obtained by FT-IR, it can be concluded that the methotrexate molecules are located perpendicularly to
the surface of the membrane, passing through the hydrophilic area up to the hydrophobic portion of
the membrane.
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The overall conclusion is that the simultaneous use of FT-IR and NMR spectroscopy allowed us
to determine the location of drugs in the liposomal membrane and the interaction between cytarabine,
methotrexate and DPPC. The complementarity of used techniques confirmed the changes observed in
the spectra such as NMR and FT-IR.
3. Materials and Methods
3.1. Materials
L-α-phosphatidylcholine dipalmitoyl (1,2-dihexadecanoyl-sn-glycerol-3-phosphocholine) (DPPC,
purity 99%), 1-β-D-arabinofuranosylcytosine (cytarabine, AraC), DL-4-Amino-N10-methylpteroylglutamic
acid (methotrexate, MTX) were purchased from Sigma-Aldrich, Schnelldorf, Germany. Chloroform,
dichloromethane, sodium hydroxide and phosphate buffered saline (PBS buffer, pH 7.4: K2HPO4,
NaH2PO4) were supplied by POCH, Gliwice, Poland. Deuterium oxide (D2O) 99%, chloroform-d 99%,
stabilized with Ag and sodium 4,4-dimethyl-4-silapentane sulfonate (DSS) were purchased from
ARMAR Chemicals, Döttingen, Switzerland.
3.2. Methods
3.2.1. Liposome Preparation
Small (diameter ≤120 nm) liposomes (LDPPC; LDPPC/AraC/MTX) were obtained by the modified
reverse-phase evaporation method (mREV) [5] using a DPPC:drug:drug molar ratio of 30:1:1. The lipid
dispersion (final lipid concentration 2.64× 10−2 M) was mixed with 0.175 mL of 5 × 10−3 M AraC and
0.175 mL of 5× 10−3 M MTX. A 2 mL PBS buffer (pH = 7.4) and a 4 mL organic solution prepared from
methylene chloride and chloroform were applied. The preparation process was carried out at 44 ◦C.
The average time of liposome preparation did not exceed 12 min. The liposome entrapped analysed
drugs were separated from the free drugs by dialysis in Float-A-Lyzer G2 (Spectra/Por) (Spectrum
Laboratories, Inc., Rancho Dominguez, CA, USA) tubing with several changes of buffer at 4 ◦C.
3.2.2. Solution and Sample Preparation
A 0.05 M phosphate buffered saline (PBS) solution with a pH adjusted to 7.4 as necessary, to mimic
physiological conditions, was prepared by dissolving 3.4836 g of K2HPO4 and 0.7800 g of NaH2PO4 in
purified water (500 mL total volume). For NMR and FT-IR measurements, deuterated solvents were
used. All solutions were prepared in triplicates.
3.2.3. Transmission Electron Microscopy (TEM)
TEM micrographs of liposome preparations before filtration were taken on Philips EM400
(100 keV accelerating voltage, Eindhoven, The Netherlands). Aliquots of liposome phospholipid
bilayer solution were placed on copper and carbon-coated grids (300 mesh, Sigma-Aldrich Chemie
GmbH, Schnelldorf, Germany). Negative staining with 2% uranyl acetate was applied to enhance
image quality. The micrographs of completely dried liposomal bilayers were acquired. A wide range
of electron beam of weak intensity (low electron density) was used to prevent sample overheating.
3.2.4. Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) scans were performed using the VP DSC ultrasensitive
microcalorimeter (MicroCal Inc., Northampton, MA, USA) with 0.5 mL cell volume. Degassing
during the calorimetric experiments was prevented by maintaining an additional constant pressure of
1.8 atm over the liquids in the cells. At first, the buffer was placed in both the sample and reference
compartments. A DSC curve corresponding to buffer vs. buffer run was used as the instrumental
baseline. The calorimetric data were corrected for the calorimetric baseline (by subtracting buffer–buffer
scan). Heat capacity vs. temperature profiles were obtained for a scanning rate of 1.0 ◦C/min
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over 10–65 ◦C temperature range. A minimum of at least three heating scans were performed for
each analysis and all thermograms were reproducible. The Origin 8.5 software package (OriginLab
Corporation, Northampton, MA, USA) was used to evaluate the transition temperatures.
3.2.5. Fourier Transform Infrared Spectroscopy
Fourier transform infrared spectra were obtained using a PerkinElmer Spectrum One FT-IR
spectrometer (Waltham, MA, USA) equipped with an IF KT-3 (Photon Institute, Krakow, Poland)
automatic temperature controller. Spectra were recorded for both dried and fully hydrated liposome
samples. For the dried samples, spectra were recorded at room temperature. The lipid dispersions were
placed in a demountable cell between two ZnSe windows separated by a 50 µm thick Teflon spacer.
For temperature regulation, the cell was placed in a thermostated jacket with internal temperature
measurement. An external water bath was used for temperature control. The temperature was
maintained at ±0.1 ◦C. All spectra were acquired after equilibrating liposome samples for 15 min at
each of the desired temperature points (20–47 ◦C range) using an automatic temperature controller.
Data acquisition was performed at intervals of 2 ◦C. For each spectrum, covering the 3000–800 cm−1
region, 10 interferograms were coadded, apodized and Fourier transformed to give a resolution
of 2 cm−1. FT-IR spectrum for the buffer was obtained under identical instrumental conditions.
Peak positions were determined with one significant digit using Spectrum v3.01 spectral processing
software (PerkinElmer Inc., Waltham, MA, USA).
3.2.6. NMR Measurements of Liposomes
1H-NMR spectra were obtained using 9.4 Tesla Bruker Avance UltraShield (400.130 MHz for 1H)
(Karlsruhe, Germany) and 5 mm inverse broadband probe (BBI). The water suppression for 1H
measurements using 3-9-19 pulse sequence with gradients was used. 1H-NMR spectra were recorded
at a temperature range of 25–47 ◦C. Sample temperature was controlled by air and monitored by the
Bruker thermal control system. The samples were heated at a rate of up to 1.0 ◦C/min and were left
for approximately 15 min to achieve equilibrium, which was monitored based on the free induction
decay (FID) signal. The temperature was maintained at ±0.1 ◦C. Water suppression was obtained by
presaturation. For 1H-NMR spectra, 32 transients were accumulated with 1H pulse length of 9.10 µs
and 5 s relaxation delay, 2.044 s acquisition time, 32,768 date points and 0.30 Hz line broadening.
Two-dimensional NOE or NOESY experiments were carried out using 500 ms mixing times, for the
detection of a build-up of NOEs. 2D NOE spectra were recorded at 25 ◦C and 47 ◦C. 1H chemical
shift values were referred to DSS as an external reference. The spectra were processed with the use of
TopSpin 3.1 (Bruker, Karlsruhe, Germany) software. Apparatus error was ±0.001 ppm.
4. Conclusions
TEM studies permitted the characterization of the shape, morphology and size of the examined
drug-loaded liposomal nanostructures. The conducted temperature analysis of symmetrical and
antisymmetrical methylene stretching bands allowed assessment of the thermotropic phase behavior
of the analyzed liposomes, and an estimation of the degree of the membrane ordering. The obtained
data are consistent with the results obtained by DSC. Application of FT-IR and NMR allowed exploring
mutual interactions between the analyzed drugs and its phospholipid carriers. The resulting degree of
encapsulation of cytarabine and methotrexate in liposomes is satisfactory and provides a good basis
for further studies of the obtained TDS.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/21/
12/1689/s1.
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